AMGN
Big win, but not the finish line
Amgen just posted encouraging topline data from its Phase 3 OASIZ 301 study of dazodalibep in Sjögren’s disease, and the drug hit its primary endpoint at 48 weeks. In plain English: the therapy showed a statistically significant and clinically meaningful improvement on the ESSDAI scale, which is the kind of data investors and regulators actually pay attention to.
Why this matters
Sjögren’s is one of those autoimmune diseases that sounds niche until you realize it can be a whole-body mess — dryness, fatigue, pain, organ involvement, neuropathy, even higher lymphoma risk. So when a drug shows real movement in a tough-to-treat condition, that’s not just lab-coat trivia. It can be the difference between a science project and a future revenue stream.
Still waiting on the second shoe
Here’s the catch: Amgen isn’t rushing to file yet. The company says it’ll share full data later at a medical conference, and analysts are still expecting that a second positive Phase 3 study, OASIZ 303, may be needed before FDA approval is on the table. That readout is projected for the fourth quarter of 2026, which means the approval timeline still has a bit of a soap-opera arc.
The investor takeaway
The stock liked the headline, with shares up 3.54% to $407.08 around publication time. But the real story is this: Amgen just de-risked a high-risk program, and in biotech, that’s often half the battle. Big picture: a good endpoint win is nice — two good endpoint wins is what gets you to the filing party.